Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
Efficacy and Safety of Different Concentrations of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yi Ji, Ph.D.
- Phone Number: +8618980606865
- Email: jijiyuanyuan@163.com
Study Contact Backup
- Name: Min Yang, M.D.
- Phone Number: +8615928411140
- Email: hx2014bsym@163.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Yi Ji, Ph.D.
- Phone Number: +8618980606865
- Email: jijiyuanyuan@163.com
-
Contact:
- Min Yang, M.D.
- Phone Number: +8615928411140
- Email: hx2014bsym@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female participants less than 14 years of age at the time of informed consent/assent form was signed.
- Participants whose parents have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them.
- Participants with LMs of all sites measured and confirmed via imaging at screening, with rapid progression, resluting in obvious symptoms or dysfunction, which could not be radically resected and could be treated by sclerotherapy.
Exclusion Criteria:
- Penicillin allergy.
- Vascular tumors or combined vascular malformations.
- Participants who may have had surgical or sclerotherapy treatment by other hardeners.
- LMs growing slowly, without obvious symptoms or dysfunction, which does not need to be treated prematurely.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Low-dose Concentrations (1mg/ml) of Bleomycin
In this arm, patients with lymphatic malformations were treated by intracapsular injection with low-dose concentrations (1mg/ml) of Bleomycin.
|
To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
Other Names:
|
|
Experimental: High-dose Concentrations (2mg/ml) of Bleomycin
In this arm, patients with lymphatic malformations were treated by intracapsular injection with high-dose concentrations (2mg/ml) of Bleomycin.
|
To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of Volume
Time Frame: 3 to 6 months post-therapy
|
Changes of Volume is defined as follows: a complete (90%-100% reduction in LMs volume), substantial (60%-89% reduction in LMs volume), intermediate (20%-59% reduction in LMs volume), or no (< 20% reduction in LMs volume) response 3 to 6 months post-therapy as assessed by imaging.
|
3 to 6 months post-therapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score of Pain
Time Frame: 3 to 6 months post-therapy
|
Score of Pain is selfassessed at each visit on a 0 to 10 visual analog scale (where 0 indicates no pain and 10 indicates the worst pain imaginable), reported along with period duration.
|
3 to 6 months post-therapy
|
|
Global Efficacy
Time Frame: 3 to 6 months post-therapy
|
Global efficacy is assessed at each visit beginning at MS by the physician and self-assessed by the participant and proxy (parents) on a 0 to 10 visual analog scale (where 0 indicates no efficacy and 10 indicates complete resolution).
|
3 to 6 months post-therapy
|
|
Score of Quality of Life
Time Frame: 3 to 6 months post-therapy
|
Score of Quality of Life is assessed by the validated Children-Dermatological Life Quality Index (C-DLQI).
|
3 to 6 months post-therapy
|
|
Number of Participants with Efficacy
Time Frame: 3 to 6 months post-therapy
|
Number of Participants with Efficacy was assessed by 2 independent experts.
|
3 to 6 months post-therapy
|
|
Number of Participants with Safety
Time Frame: 3 to 6 months post-therapy
|
Number of Participants with Safety was assessed based on physical signs and monitoring of imaging examinations or laboratory test.
|
3 to 6 months post-therapy
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Sun J, Wang C, Li J, Song D, Guo L. The efficacy of bleomycin sclerotherapy in the treatment of lymphatic malformations: a review and meta-analysis. Braz J Otorhinolaryngol. 2023 Jul-Aug;89(4):101285. doi: 10.1016/j.bjorl.2023.101285. Epub 2023 Jun 29.
- De Maria L, De Sanctis P, Balakrishnan K, Tollefson M, Brinjikji W. Sclerotherapy for lymphatic malformations of head and neck: Systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord. 2020 Jan;8(1):154-164. doi: 10.1016/j.jvsv.2019.09.007. Epub 2019 Nov 14.
- Wu Z, Zou Y, Fu R, Jin P, Yuan H. A nomogram for predicting sclerotherapy response for treatment of lymphatic malformations in children. Eur J Med Res. 2022 Oct 21;27(1):209. doi: 10.1186/s40001-022-00844-3.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-12-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.